Japan Entry Acceleration Program​ 2025
   Application Form for Regenerative Medicine/Cell & Gene Therapy Startups

     Application Period: Monday, September 8, 2025 – Friday, October 31, 2025
     Selection Period: November 2025
     Notice of Selection: End of November


 

 

Important Note:

  1. * indicates a requred field.
  2. This form contains multiple answer fields. To prevent accidental loss of your responses due to misclicks or page refreshes, we strongly recommend reviewing all questions first, drafting your answers in a separate document (e.g., Notepad), and then copying and pasting them into the form once everything is ready.
Privacy Notice
  1. Personal information and responses provided will be appropriately managed and handled in accordance with JETRO’s Privacy Policy. 
  2. Program operations of this acceleration program have been entrusted to program coordination partner and mentors who may access your application details for operational purposes.
  3. Non-confidential information may also be shared with relevant stakeholders in Japan (e.g., CDMOs or CROs affiliated with mentors) to explore potential collaboration.
  4. If any stakeholder expresses interest, JETRO will first contact your company to confirm your interest and obtain consent before sharing company-specific details or arranging the meeting. This process may occur regardless of program selection and could lead to your business opportunities outside the formal program. However, please note that sharing your information does not guarantee a meeting or collaboration offer from these stakeholders.
  5. By submitting your application, you agree that the information entered on this page may be shared with the above company for the purpose of program operation.
*

Please check “Agree” to confirm your understanding and acceptance of the above.

1. Basic Information
* 1-1. Company name
* 1-2. Country
* 1-3. State / Province / Region
* 1-4. Street Address
1-5. Company URL if any
* 1-6. Department
* 1-7. Contact person
* 1-8. Title
* 1-9. Email
* 1-10. Do you have any in-house clinical development candidates or pipelines?
* 1-11. Choose the main focus of your business. (Multiple selections)
2. Technology and Products
* 2-1. Technology and product type (multiple selections)
* 2-2. Please provide a brief overview of the technology and product. (Free text)
* 2-3.  What is unique or innovative about your technology/product? (Free text)
* 2-4. Scientific basis (select all that apply)
* 2-5. Please describe the scientific basis (non-clinical data, clinical data, papers, etc.). (Free text)    
* 2-6. Intellectual Property Status (Multiple Selections)　
3. Business growth potential
* 3-1. Development stage
* 3-2.  Please specify the countries where each development phase (Phase 1 and beyond) has been conducted.
If multiple countries are involved, please list all of them.
* 3-3. Select your target market (main indicated disease area). (Multiple selections available) 
3-4. Please provide the specific disease name for your target market (main indicated disease area).  
* 3-5. Please indicate the target market size at the time the product is expected to be launched (based on annual sales). 
* 3-6. Revenue Model
* 3-7. Status of clinical trial sample production
4. Interest in the Japan market
* 4-1. Intention to cooperate with Japanese companies (multiple choices allowed) Required
* 4-2. Collaboration experience with Japanese companies
* 4-3. If yes, please provide more details
* 4-4. Japanese language capability
* 4-5. Specific plans for entering the Japan market (Free text)    
5. Team performance and execution ability
* 5-1. Management experience (multiple choices allowed) Required
* 5-2. Organizational structure
* 5-3. Cumulative Amount Raised in USD
5-4. Please fill in if you have a track record of investment from a well-known VC or pharmaceutical company.
6. Launch span in Japan *Required
* 6-1. Estimated timing for launching your product in Japanese market
* 6-2. Your expected Milestones for Entering the Japanese Market (multiple choices allowed)
* 6-3. Possibility of clinical trials in Japan
7. Availability of Decision-Makers to Participate
*

7-1. Please list the name and title of any C-level executive or person responsible for overseas expansion who may participate in the program.

* 7-2. Would you available to attend the Demo Day in Japan (Scheduled for February 2026)
8. Preference for Survey Participation
* 8-1. Are you willing to participate in a survey or a quick interview after the program ends?
9. Attachments
* 9-1-1. Pitch Deck (PDF)
*Max 10,000 KB
* 9-1-2. Pitch Deck (Optional – for large files)
*Each upload section allows a maximum file size of 10,000KB. If your pitch deck exceeds this limit, please split the file into two parts and upload the second part here. This section is optional and intended for overflow use only.


 
9-2. Technical Documents (PDF)
*Max 10,000 KB
9-3. Please list any relevant patents or academic publications if any.
Example:
Patent:
WO2023/123456 (PCT/JP2023/000001), filed in Japan and the U.S. — Method for producing cardiomyocytes derived from iPSCs
Publication:
Yamada T. et al., “iPSC-derived NK cells for solid tumors,” Nature Medicine, 2022, DOI:xxxx
9-4. Referral by JETRO staff (if any)
Please enter the full name and office location of the JETRO staff member who referred your company.




Copyright (C) 1995-2025 Japan External Trade Organization(JETRO). All rights reserved.